Journal article Open Access

Impact of a Daily Probiotic (Lactobacillus casei Shirota) for 12 Months on the Frequency of Diverticulitis Episodes: Feasibility Study in Primary Care.

John Nichols*; Barbara Engel; Linda V. Thomas; Paul Grob; Michelle Dobrota Gibbs; Peter Williams; Tamara Fenton; Simon de Lusignan


Citation Style Language JSON Export

{
  "publisher": "Zenodo", 
  "DOI": "10.5281/zenodo.3755563", 
  "container_title": "Archives of Nutrition and Public Health", 
  "title": "Impact of a Daily Probiotic (Lactobacillus casei Shirota) for 12 Months on the Frequency of Diverticulitis Episodes: Feasibility Study in Primary Care.", 
  "issued": {
    "date-parts": [
      [
        2020, 
        3, 
        25
      ]
    ]
  }, 
  "abstract": "<p><strong>Background:</strong>Some small secondary care studies have shown benefits from taking probiotics in diverticular disease. We investigated the feasibility of conducting a year-long probiotic study in primary care.</p>\n\n<p><strong>Methods:</strong>Patients (n=21) with a past history of uncomplicated acute diverticulitis but not currently taking antibiotics were recruited from four general practices. Subjects were asked to take the daily probiotic drink Yakult&Ograve;. Probiotic effects were assessed by comparing clinically diagnosed diverticulitis attacks in the 6 months prior to probiotic intervention with the 0-6 and 6-12 month periods after probiotic intervention commenced. Effects on gastrointestinal symptoms were assessed by validated questionnaires at baseline, 6 and 12 months. Diet diaries were also completed.</p>\n\n<p><strong>Results: </strong>Two thirds (14/21) of subjects who demonstrated good adherence in taking the daily probiotic improved symptomatically (p=0.025). Clinical presentations with diverticulitis were down 50% during the study period compared with the 12 months period before (7 vs 14 cases; p=0.021). The mean change in gastrointestinal symptom score improved significantly (p &lt;0.001). Diverticulitis episodes did not correlate with body mass index (BMI), diabetic status or dietary fibre.&nbsp;</p>\n\n<p><strong>Conclusions: </strong>Taking the daily probiotic was associated with a lower rate of clinical presentation with diverticulitis episodes and improvement in gastrointestinal symptoms. Sufficient information is presented to design a definitive trial. However, we recommend inclusion of a method to validate the diagnosis of diverticulitis. It is feasible to recruit and run a study that requires participants to take a daily probiotic drink for a year in a primary care setting.</p>\n\n<p>LACTOPRoD was registered at ClinicalTrials.gov:&nbsp;NCT01609751 in 2012.</p>", 
  "author": [
    {
      "family": "John Nichols*"
    }, 
    {
      "family": "Barbara Engel"
    }, 
    {
      "family": "Linda V. Thomas"
    }, 
    {
      "family": "Paul Grob"
    }, 
    {
      "family": "Michelle Dobrota Gibbs"
    }, 
    {
      "family": "Peter Williams"
    }, 
    {
      "family": "Tamara Fenton"
    }, 
    {
      "family": "Simon de Lusignan"
    }
  ], 
  "page": "1-10", 
  "volume": "2", 
  "type": "article-journal", 
  "issue": "1", 
  "id": "3755563"
}
581
46
views
downloads
All versions This version
Views 581581
Downloads 4646
Data volume 26.2 MB26.2 MB
Unique views 438438
Unique downloads 4444

Share

Cite as